AU2018216969B2 - Cancer treatment - Google Patents

Cancer treatment Download PDF

Info

Publication number
AU2018216969B2
AU2018216969B2 AU2018216969A AU2018216969A AU2018216969B2 AU 2018216969 B2 AU2018216969 B2 AU 2018216969B2 AU 2018216969 A AU2018216969 A AU 2018216969A AU 2018216969 A AU2018216969 A AU 2018216969A AU 2018216969 B2 AU2018216969 B2 AU 2018216969B2
Authority
AU
Australia
Prior art keywords
erdafitinib
treatment
serum phosphate
cancer
phosphate levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018216969A
Other languages
English (en)
Other versions
AU2018216969A1 (en
Inventor
Anjali Narayan Avadhani
Peter Marie Z. De Porre
Yohann LORIOT
Anne Elizabeth O’Hagan
Juan Jose Perez Ruixo
Arlene O. Siefker-Radtke
Kim STUYCKENS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018216969(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority claimed from PCT/EP2018/052694 external-priority patent/WO2018141921A1/en
Publication of AU2018216969A1 publication Critical patent/AU2018216969A1/en
Priority to AU2024201871A priority Critical patent/AU2024201871A1/en
Application granted granted Critical
Publication of AU2018216969B2 publication Critical patent/AU2018216969B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Laminated Bodies (AREA)
AU2018216969A 2017-02-06 2018-02-02 Cancer treatment Active AU2018216969B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024201871A AU2024201871A1 (en) 2017-02-06 2024-03-22 Cancer treatment

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
US62/455211 2017-02-06
EP17209098 2017-12-20
EP17209098.7 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024201871A Division AU2024201871A1 (en) 2017-02-06 2024-03-22 Cancer treatment

Publications (2)

Publication Number Publication Date
AU2018216969A1 AU2018216969A1 (en) 2019-07-25
AU2018216969B2 true AU2018216969B2 (en) 2024-04-11

Family

ID=61094531

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018216969A Active AU2018216969B2 (en) 2017-02-06 2018-02-02 Cancer treatment
AU2024201871A Pending AU2024201871A1 (en) 2017-02-06 2024-03-22 Cancer treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024201871A Pending AU2024201871A1 (en) 2017-02-06 2024-03-22 Cancer treatment

Country Status (25)

Country Link
US (2) US11077106B2 (enExample)
EP (2) EP4286005A3 (enExample)
JP (3) JP2020505425A (enExample)
KR (2) KR20190110581A (enExample)
CN (1) CN110198716A (enExample)
AU (2) AU2018216969B2 (enExample)
BR (1) BR112019016043A2 (enExample)
CA (1) CA3049737A1 (enExample)
DK (1) DK3576740T3 (enExample)
ES (1) ES2953005T3 (enExample)
FI (1) FI3576740T3 (enExample)
HR (1) HRP20230697T1 (enExample)
HU (1) HUE062453T2 (enExample)
IL (1) IL268463A (enExample)
JO (1) JOP20190190A1 (enExample)
LT (1) LT3576740T (enExample)
MX (2) MX2019009304A (enExample)
PH (1) PH12019501885A1 (enExample)
PL (1) PL3576740T3 (enExample)
RS (1) RS64778B1 (enExample)
SG (2) SG10202105110VA (enExample)
SI (1) SI3576740T1 (enExample)
SM (1) SMT202300233T1 (enExample)
TW (1) TWI874925B (enExample)
UA (1) UA126336C2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
SMT202200177T1 (it) 2014-09-26 2022-05-12 Janssen Pharmaceutica Nv Uso di gruppi di geni mutanti del fgfr nell'identificazione di pazienti affetti da cancro che saranno responsivi al trattamento con un inibitore del fgfr
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
MA54932A (fr) * 2019-02-12 2021-12-22 Janssen Pharmaceutica Nv Traitement contre le cancer
WO2020205493A1 (en) * 2019-03-29 2020-10-08 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
EP3946340A1 (en) * 2019-03-29 2022-02-09 Janssen Pharmaceutica NV Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
AU2021220285A1 (en) * 2020-02-12 2022-10-06 Janssen Pharmaceutica Nv FGFR tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物
TW202508591A (zh) * 2023-05-24 2025-03-01 比利時商健生藥品公司 癌症治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128411A1 (en) * 2015-02-10 2016-08-18 Astex Therapeutics Limited Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128411A1 (en) * 2015-02-10 2016-08-18 Astex Therapeutics Limited Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. CLIN. ONCOL., vol. 33, no. 30, JPN6021047113, 2015, pages 3401 - 3408, ISSN: 0004650038 *
POSTER 845TiP: Siefker-Radtke et al. "Ongoing Phase 2 Study of Erdafitinib (JNJ-42756493), a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor..." European Society for Medical Oncology 2016 Congress, 2016 October 7-11. *

Also Published As

Publication number Publication date
PH12019501885A1 (en) 2020-06-29
EP3576740B1 (en) 2023-06-14
BR112019016043A2 (pt) 2020-03-31
CA3049737A1 (en) 2018-08-09
JOP20190190A1 (ar) 2019-08-04
DK3576740T3 (da) 2023-07-24
US20220110935A1 (en) 2022-04-14
UA126336C2 (uk) 2022-09-21
JP2020505425A (ja) 2020-02-20
HRP20230697T1 (hr) 2023-10-13
US20200022976A1 (en) 2020-01-23
HUE062453T2 (hu) 2023-11-28
JP2025024064A (ja) 2025-02-19
US11077106B2 (en) 2021-08-03
EP4286005A3 (en) 2024-03-06
ES2953005T3 (es) 2023-11-07
EP3576740A1 (en) 2019-12-11
AU2018216969A1 (en) 2019-07-25
LT3576740T (lt) 2023-08-10
SI3576740T1 (sl) 2023-10-30
SG10202105110VA (en) 2021-06-29
FI3576740T3 (fi) 2023-08-31
AU2024201871A1 (en) 2024-04-11
EP4286005A2 (en) 2023-12-06
MX2022007955A (es) 2022-07-27
PL3576740T3 (pl) 2023-09-11
JP7668777B2 (ja) 2025-04-25
KR20250069693A (ko) 2025-05-19
TW202402290A (zh) 2024-01-16
SG11201907199QA (en) 2019-09-27
JP2023022190A (ja) 2023-02-14
IL268463A (en) 2019-09-26
SMT202300233T1 (it) 2023-09-06
TWI874925B (zh) 2025-03-01
KR20190110581A (ko) 2019-09-30
MX2019009304A (es) 2019-09-19
CN110198716A (zh) 2019-09-03
RS64778B1 (sr) 2023-11-30

Similar Documents

Publication Publication Date Title
AU2018216969B2 (en) Cancer treatment
WO2018141921A1 (en) Cancer treatment
US11707463B2 (en) FGFR2 inhibitors for the treatment of cholangiocarcinoma
AU2020223467B2 (en) Cancer treatment
HK40103983A (en) Cancer treatment
HK40018978B (en) Cancer treatment
HK40018978A (en) Cancer treatment
AU2020253827A1 (en) FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40013982A (en) Cancer treatment

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ STUYCKENS, KIM; PEREZ RUIXO, JUAN JOSE; DE PORRE, PETER MARIE Z.; AVADHANI, ANJALI NARAYAN; LORIOT, YOHANN; SIEFKER-RADTKE, ARLENE O. AND O'HAGAN, ANNE

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ STUYCKENS, KIM; PEREZ RUIXO, JUAN JOSE; DE PORRE, PETER MARIE Z.; AVADHANI, ANJALI NARAYAN; LORIOT, YOHANN; SIEFKER-RADTKE, ARLENE O. AND O'HAGAN, ANNE ELIZABETH

FGA Letters patent sealed or granted (standard patent)